Pediatrix Medical Group (MD) Financials

$13.84 +0.28 (+2.06%)

Closing price 05/27/2025 03:59 PM Eastern

Extended Trading

$13.85 +0.01 (+0.07%)

As of 05/27/2025 05:48 PM Eastern

Annual Income Statements for Pediatrix Medical Group

This table shows Pediatrix Medical Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	-99	-60	66	131	-796	-1,498	269	320	325	336	317
Consolidated Net Income / (Loss)	-99	-60	66	131	-796	-1,498	269	320	325	336	317
Net Income / (Loss) Continuing Operations	-99	-60	63	108	-9.58	42	122	305	325	336	317
Total Pre-Tax Income	-101	-48	81	135	7.15	59	166	386	514	540	509
Total Operating Income	-69	7.32	173	203	98	172	248	455	572	558	513
Total Gross Profit	2,013	1,995	1,972	1,911	1,734	1,780	1,723	3,253	3,183	2,780	2,439
Total Revenue	2,013	1,995	1,972	1,911	1,734	1,780	1,723	3,253	3,183	2,780	2,439
Operating Revenue	2,013	1,995	1,972	1,911	1,734	1,780	1,723	3,253	3,183	2,780	2,439
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	2,082	1,987	1,799	1,723	1,636	1,608	1,475	2,798	2,611	2,222	1,926
Selling, General & Admin Expense	1,679	1,676	1,615	1,561	1,443	1,425	1,358	2,613	2,404	2,059	1,791
Depreciation Expense	32	36	36	32	28	26	24	79	89	64	46
Other Operating Expenses / (Income)	127	125	122	100	91	96	92	106	118	98	89
Impairment Charge	178	148	0.00	0.00	-	-	-	0.00	-	-	-
Restructuring Charge	64	2.22	27	22	74	61	0.00	0.00	-	-	-
Total Other Income / (Expense), net	-33	-56	-91	-68	-91	-113	-82	-69	-58	-18	-4.38
Interest Expense	41	42	97	83	110	119	93	75	63	23	8.89
Interest & Investment Income	8.12	6.40	5.39	16	19	5.96	11	5.34	5.20	4.97	4.51
Other Income / (Expense), net	0.00	-20	0.00	0.00	-	0.00	-	-	-	-	-
Income Tax Expense	-2.27	12	19	27	17	17	45	80	189	204	191
Net Income / (Loss) Discontinued Operations	0.00	0.00	3.77	23	-787	-1,540	147	15	-	-	-
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	0.00	-0.00	-0.03	0.00	0.00	-	-	-0.32	-0.63	-0.08
Basic Earnings per Share	($1.19)	($0.73)	$0.79	$1.54	($9.55)	($17.94)	$2.95	$3.47	$3.52	$3.61	$3.22
Weighted Average Basic Shares Outstanding	83.33M	82.20M	83.47M	84.83M	83.40M	83.50M	91.10M	92.43M	92.42M	93.08M	98.59M
Diluted Earnings per Share	($1.19)	($0.73)	$0.79	$1.53	($9.55)	($17.83)	$2.93	$3.45	$3.49	$3.58	$3.18
Weighted Average Diluted Shares Outstanding	83.33M	82.20M	84.12M	85.83M	83.40M	84.01M	91.61M	92.96M	93.11M	93.96M	99.89M
Weighted Average Basic & Diluted Shares Outstanding	85.83M	84.12M	83.03M	86.47M	85.63M	84.28M	91.10M	92.30M	93.79M	93.20M	98.50M

This table shows Pediatrix Medical Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	22	28	21	-153	4.10	-125	21	28	15	30	31
Consolidated Net Income / (Loss)	21	30	19	-153	4.04	-124	21	28	14	30	31
Net Income / (Loss) Continuing Operations	21	30	19	-153	4.04	-124	21	28	14	24	29
Total Pre-Tax Income	28	33	25	-168	7.82	-139	31	39	21	28	39
Total Operating Income	32	39	34	-158	16	-111	40	48	30	36	47
Total Gross Profit	458	502	511	504	495	496	507	501	491	514	490
Total Revenue	458	502	511	504	495	496	507	501	491	514	490
Operating Revenue	458	502	511	504	495	496	507	501	491	514	490
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	426	463	477	662	479	608	466	452	461	478	443
Selling, General & Admin Expense	396	413	423	414	429	417	426	412	421	418	401
Depreciation Expense	5.33	6.87	6.25	8.79	10	9.06	9.21	8.95	8.95	9.14	8.96
Other Operating Expenses / (Income)	19	24	30	43	31	32	31	31	31	31	32
Restructuring Charge	6.61	24	19	14	8.48	2.22	0.00	0.00	0.00	20	0.98
Total Other Income / (Expense), net	-4.01	-5.96	-8.59	-10	-8.07	-27	-9.44	-9.55	-9.33	-8.21	-8.53
Interest Expense	9.15	9.71	10	10	11	10	10	11	10	9.95	9.52
Interest & Investment Income	5.14	3.75	1.53	0.30	2.53	2.72	0.93	1.68	1.06	1.74	0.99
Income Tax Expense	7.35	2.85	5.79	-15	3.79	-15	9.44	11	6.51	3.82	10
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-0.78	-	-1.75	-0.20	-0.06	-	-	0.39	-0.60	-	-
Basic Earnings per Share	$0.25	$0.37	$0.23	($1.84)	$0.05	($1.50)	$0.26	$0.34	$0.17	$0.35	$0.37
Weighted Average Basic Shares Outstanding	84.44M	83.33M	83.89M	83.33M	82.86M	82.20M	82.54M	82.40M	81.89M	83.47M	82.13M
Diluted Earnings per Share	$0.24	$0.37	$0.23	($1.84)	$0.05	($1.50)	$0.26	$0.34	$0.17	$0.35	$0.37
Weighted Average Diluted Shares Outstanding	85.43M	83.33M	84.52M	83.33M	83.28M	82.20M	82.95M	82.66M	82.32M	84.12M	82.78M
Weighted Average Basic & Diluted Shares Outstanding	85.91M	85.83M	85.88M	85.87M	84.15M	84.12M	84.02M	83.94M	83.76M	83.03M	83.07M

This table details how cash moves in and out of Pediatrix Medical Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	157	63	-378	-736	1,016	161	0.33	25	4.13	3.64	17
Net Cash From Operating Activities	207	137	167	77	205	358	314	511	444	369	423
Net Cash From Continuing Operating Activities	217	146	182	114	154	74	59	483	444	369	423
Net Income / (Loss) Continuing Operations	-99	-60	63	108	-9.58	42	122	305	325	336	317
Consolidated Net Income / (Loss)	-99	-60	66	131	-796	-1,498	269	320	325	336	317
Net Income / (Loss) Discontinued Operations	0.00	0.00	3.77	23	-787	-1,540	147	15	-	-	-
Depreciation Expense	32	36	36	32	28	26	24	79	89	64	46
Amortization Expense	0.95	1.24	1.77	4.34	7.16	5.67	4.57	5.51	4.82	1.54	1.23
Non-Cash Adjustments To Reconcile Net Income	197	177	73	38	39	40	34	51	31	31	26
Changes in Operating Assets and Liabilities, net	86	-8.39	9.06	-55	89	-40	-125	42	-5.66	-64	32
Net Cash From Discontinued Operating Activities	-11	-8.76	-15	-37	51	284	255	28	-	-	-
Net Cash From Investing Activities	-35	-48	-57	-53	816	102	-143	-577	-821	-848	-504
Net Cash From Continuing Investing Activities	-35	-48	-57	-55	-58	-50	-85	-553	-821	-848	-504
Purchase of Property, Plant & Equipment	-22	-33	-30	-32	-29	-19	-17	-26	-39	-27	-18
Acquisitions	-8.17	-6.67	-28	-30	-2.23	47	-65	-531	-762	-819	-479
Purchase of Investments	-65	-32	-17	-35	-62	-35	-16	-28	-61	-34	-27
Sale of Property, Plant & Equipment	6.84	0.81	1.38	25	1.08	0.00	-	-	-	-	-
Sale and/or Maturity of Investments	52	23	17	16	33	51	14	25	41	32	21
Net Cash From Financing Activities	-14	-26	-488	-760	-4.16	-393	-171	90	382	483	98
Net Cash From Continuing Financing Activities	0.00	0.00	0.00	-760	-2.91	-384	-169	90	382	483	98
Repayment of Debt	-248	-495	-1,882	-759	-528	-1,996	-2,102	-2,704	-1,512	-2,172	-1,218
Repurchase of Common Equity	-1.70	-0.92	-89	-4.72	-8.49	-145	-302	-70	-62	-235	-488
Issuance of Debt	236	470	1,480	0.00	528	1,747	2,224	2,846	1,940	2,872	1,755
Issuance of Common Equity	3.64	4.91	5.40	6.85	7.25	11	16	24	22	20	44
Other Financing Activities, net	-4.06	-4.44	-2.92	-3.00	-1.16	-1.39	-5.26	-5.45	-6.50	-1.27	5.72
Net Cash From Discontinued Financing Activities	0.00	0.00	0.00	0.00	-1.25	-8.96	-1.36	-0.61	-	-	-
Cash Interest Paid	40	42	116	87	110	95	83	74	60	20	7.32
Cash Income Taxes Paid	4.67	31	27	55	-28	86	185	75	176	181	162

This table details how cash moves in and out of Pediatrix Medical Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-131	126	84	11	-65	52	15	-0.28	-3.70	1.16	-5.42
Net Cash From Operating Activities	-117	133	92	107	-125	69	80	89	-101	99	83
Net Cash From Continuing Operating Activities	-116	135	96	109	-123	73	81	93	-101	102	88
Net Income / (Loss) Continuing Operations	21	30	19	-153	4.04	-124	21	28	14	24	29
Consolidated Net Income / (Loss)	21	30	19	-153	4.04	-124	21	28	14	30	31
Depreciation Expense	5.33	6.87	6.25	8.79	10	9.06	9.21	8.95	8.95	9.14	8.96
Amortization Expense	0.23	0.25	0.26	0.24	0.20	0.22	0.28	0.34	0.39	0.42	0.49
Non-Cash Adjustments To Reconcile Net Income	2.88	-3.06	3.84	194	1.80	170	2.46	2.62	2.62	5.76	3.32
Changes in Operating Assets and Liabilities, net	-145	100	66	59	-139	18	48	52	-127	63	47
Net Cash From Discontinued Operating Activities	-1.35	-1.80	-3.89	-2.39	-2.60	-3.75	-1.18	-3.55	-0.27	-3.61	-5.02
Net Cash From Investing Activities	-7.46	-1.94	-4.34	-13	-16	-12	-14	-10	-11	-11	-6.09
Net Cash From Continuing Investing Activities	-7.46	-1.94	-4.34	-29	0.00	-12	-14	-22	0.00	-57	-
Purchase of Property, Plant & Equipment	-3.32	-3.44	-6.29	-6.96	-5.33	-9.04	-9.15	-8.13	-7.00	-9.06	-6.95
Acquisitions	0.00	-	-	-	-8.17	-5.00	-	-	-1.67	-	-
Purchase of Investments	-7.76	-10	-14	-23	-17	-5.42	-8.72	-8.21	-9.55	-2.41	-1.96
Sale and/or Maturity of Investments	7.30	7.17	14	17	14	6.35	3.75	5.95	6.87	1.00	1.85
Other Investing Activities, net	-3.69	-	-	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	-6.04	-4.96	-3.07	-83	76	-4.75	-51	-79	109	-86	-83
Net Cash From Continuing Financing Activities	-6.04	9.52	-3.07	-83	76	21	-51	-79	109	401	-83
Repayment of Debt	-4.79	-12	6.22	-148	-94	-3.45	-100	-285	-107	-241	-261
Repurchase of Common Equity	-1.57	-0.64	-0.16	-0.01	-0.89	-	-0.13	-0.01	-0.78	-1.47	-21
Issuance of Debt	0.00	-	-	65	171	-	49	205	216	156	200
Issuance of Common Equity	0.66	0.73	0.90	1.15	0.86	1.04	1.19	1.59	1.10	1.18	1.38
Other Financing Activities, net	-0.34	7.37	-10	-0.70	-0.69	-2.33	-0.70	-0.70	-0.70	-0.74	-0.91

This table presents Pediatrix Medical Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	2,153	2,220	2,348	2,723	3,348	4,146	5,937	5,867	5,339	4,547	3,608
Total Current Assets	640	483	428	841	1,549	732	660	627	587	528	467
Cash & Equivalents	230	73	9.82	387	1,124	108	25	60	56	52	48
Short-Term Investments	119	104	93	100	105	75	22	10	11	8.85	6.04
Accounts Receivable	260	272	297	302	242	434	507	504	495	445	352
Prepaid Expenses	13	14	15	19	17	17	17	16	11	9.64	7.04
Current Deferred & Refundable Income Taxes	13	7.57	0.00	14	0.00	-	-	-	-	-	46
Other Current Assets	5.09	12	13	19	62	12	17	37	14	13	7.90
Plant, Property, & Equipment, net	39	76	73	70	76	73	90	124	103	84	66
Total Noncurrent Assets	1,474	1,661	1,847	1,812	1,722	3,342	5,187	5,117	4,649	3,936	3,075
Goodwill	1,243	1,384	1,532	1,505	1,478	1,480	4,061	4,284	3,845	3,366	2,776
Intangible Assets	12	21	18	22	27	29	313	640	669	424	198
Noncurrent Deferred & Refundable Income Taxes	104	103	106	88	54	87	22	-	-	-	-
Other Noncurrent Operating Assets	116	152	190	196	163	105	81	112	57	82	37
Total Liabilities & Shareholders' Equity	2,153	2,220	2,348	2,723	3,348	4,146	5,937	5,867	5,339	4,547	3,608
Total Liabilities	1,388	1,371	1,456	1,826	2,600	2,647	2,850	2,801	2,579	2,109	1,343
Total Current Liabilities	434	389	427	427	444	542	503	531	449	429	416
Short-Term Debt	21	15	15	2.49	-	-	0.25	1.40	22	12	10
Accounts Payable	399	351	374	394	423	411	449	438	408	396	381
Current Deferred & Payable Income Tax Liabilities	2.17	2.16	16	11	0.00	6.04	31	92	19	21	25
Other Current Liabilities	13	21	22	20	21	18	0.00	-	-	-	-
Total Noncurrent Liabilities	954	982	1,029	1,398	2,156	2,105	2,347	2,269	2,130	1,681	926
Long-Term Debt	597	618	636	0.00	1,743	1,730	1,974	1,851	1,684	1,263	558
Noncurrent Deferred & Payable Income Tax Liabilities	34	34	34	41	62	56	96	148	228	189	160
Other Noncurrent Operating Liabilities	322	329	359	1,357	352	272	241	270	218	229	208
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	765	849	892	897	748	1,499	3,088	3,066	2,761	2,438	2,266
Total Preferred & Common Equity	765	849	892	896	747	1,499	3,088	3,066	2,761	2,438	2,265
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	765	849	892	896	747	1,499	3,088	3,066	2,761	2,438	2,265
Common Stock	1,015	1,001	984	1,051	1,030	989	994	1,018	975	927	888
Retained Earnings	-249	-149	-89	-155	-286	510	2,094	2,048	1,786	1,510	1,377
Accumulated Other Comprehensive Income / (Loss)	-1.07	-2.21	-3.74	1.32	3.53	0.08	-	-	-	-	-

This table presents Pediatrix Medical Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,993	2,077	1,995	2,168	2,326	2,306	2,320	2,332
Total Current Assets	492	528	429	427	421	398	409	424
Cash & Equivalents	99	104	19	8.00	21	5.85	6.12	8.67
Short-Term Investments	120	117	114	107	104	98	97	91
Accounts Receivable	243	287	274	284	277	271	279	294
Prepaid Expenses	12	10	12	13	11	12	15	9.66
Current Deferred & Refundable Income Taxes	10	1.20	0.00	5.19	-	-	-	9.73
Other Current Assets	7.61	9.48	9.94	9.58	7.87	10	12	9.90
Plant, Property, & Equipment, net	38	42	48	74	75	73	73	72
Total Noncurrent Assets	1,464	1,507	1,518	1,667	1,831	1,834	1,839	1,837
Noncurrent Note & Lease Receivables	40	-	-	70	-	-	67	-
Goodwill	1,243	1,239	1,239	1,393	1,532	1,532	1,532	1,532
Intangible Assets	10	13	10	19	15	17	17	20
Noncurrent Deferred & Refundable Income Taxes	99	119	124	102	103	102	103	98
Other Noncurrent Operating Assets	71	135	145	83	180	184	119	187
Total Liabilities & Shareholders' Equity	1,993	2,077	1,995	2,168	2,326	2,306	2,320	2,332
Total Liabilities	1,204	1,344	1,289	1,312	1,358	1,363	1,410	1,473
Total Current Liabilities	271	373	310	247	350	320	284	352
Short-Term Debt	22	19	18	16	15	15	15	15
Accounts Payable	234	333	267	207	303	278	227	306
Current Deferred & Payable Income Tax Liabilities	2.58	3.32	6.33	2.80	11	6.15	22	7.66
Other Current Liabilities	12	17	19	21	22	22	21	23
Total Noncurrent Liabilities	933	971	979	1,065	1,008	1,043	1,126	1,122
Long-Term Debt	590	0.00	0.00	80	622	666	114	731
Noncurrent Deferred & Payable Income Tax Liabilities	34	36	31	34	41	38	33	40
Other Noncurrent Operating Liabilities	308	936	948	951	345	339	979	351
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	789	732	706	856	968	942	910	859
Total Preferred & Common Equity	789	732	706	856	968	942	910	859
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	789	732	706	856	968	942	910	859
Common Stock	1,017	1,012	1,007	1,004	997	992	988	981
Retained Earnings	-228	-279	-298	-145	-25	-47	-75	-119
Accumulated Other Comprehensive Income / (Loss)	-0.29	-0.21	-1.95	-2.15	-3.52	-3.52	-3.13	-4.10

This table displays calculated financial ratios and metrics derived from Pediatrix Medical Group's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.92%	1.15%	3.18%	10.22%	-2.57%	3.29%	-47.04%	2.21%	14.50%	13.99%	13.23%
EBITDA Growth	-243.68%	-88.23%	-12.24%	79.01%	-34.24%	-26.67%	-48.58%	-19.00%	6.76%	11.32%	13.84%
EBIT Growth	-441.94%	-107.34%	-14.90%	106.78%	-42.87%	-30.85%	-45.40%	-20.43%	2.48%	8.75%	13.46%
NOPAT Growth	-1,038.57%	-96.14%	-18.06%	223.21%	-206.65%	-32.09%	-49.59%	-0.25%	4.09%	8.45%	13.11%
Net Income Growth	-64.00%	-191.07%	-49.34%	116.44%	46.82%	-657.54%	-16.15%	-1.30%	-3.31%	5.83%	13.08%
EPS Growth	-63.01%	-192.41%	-48.37%	116.02%	46.44%	-708.53%	-15.07%	-1.15%	-2.51%	12.58%	14.39%
Operating Cash Flow Growth	50.43%	-17.74%	117.55%	-62.50%	-42.80%	14.03%	-38.65%	15.23%	20.36%	-12.76%	4.25%
Free Cash Flow Firm Growth	58.53%	115.68%	-188.48%	1,178.17%	-97.31%	348.77%	851.15%	76.42%	29.51%	-333.50%	-208.28%
Invested Capital Growth	-20.74%	-9.39%	249.41%	-67.34%	-14.31%	-65.71%	-9.95%	10.36%	20.39%	32.12%	19.39%
Revenue Q/Q Growth	0.30%	-0.86%	0.78%	4.48%	41.00%	73.79%	-47.34%	-3.70%	2.88%	3.39%	3.53%
EBITDA Q/Q Growth	80.70%	-87.15%	-12.89%	16.32%	58.31%	114.35%	-44.13%	-10.67%	-0.10%	2.58%	4.05%
EBIT Q/Q Growth	68.69%	-108.19%	-15.62%	21.35%	91.77%	58.25%	-41.80%	-8.50%	-1.41%	1.80%	3.46%
NOPAT Q/Q Growth	68.69%	-95.54%	-11.90%	23.58%	-467.16%	62.32%	-52.48%	18.80%	-2.64%	2.09%	3.35%
Net Income Q/Q Growth	60.97%	-164.58%	-21.21%	584.42%	-10.19%	-3.52%	-22.03%	22.12%	-4.23%	1.25%	3.02%
EPS Q/Q Growth	25.63%	-165.18%	-20.20%	800.00%	-12.22%	-2.59%	-21.02%	22.34%	-4.90%	0.28%	2.25%
Operating Cash Flow Q/Q Growth	44.65%	-17.65%	48.40%	271.88%	-41.83%	-4.30%	-12.36%	14.48%	6.43%	-16.84%	10.33%
Free Cash Flow Firm Q/Q Growth	-72.02%	0.48%	7.21%	244.09%	-97.74%	52.66%	489.25%	-660.18%	1.18%	8.64%	-77.61%
Invested Capital Q/Q Growth	94.63%	-11.84%	-4.30%	5.86%	384.20%	-51.24%	-11.88%	3.62%	0.16%	0.59%	2.40%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-1.77%	1.24%	10.65%	12.53%	7.71%	11.43%	16.09%	16.58%	20.92%	22.43%	22.97%
Operating Margin	-3.41%	0.37%	8.76%	10.62%	5.66%	9.65%	14.42%	13.98%	17.96%	20.07%	21.03%
EBIT Margin	-3.41%	-0.64%	8.76%	10.62%	5.66%	9.65%	14.42%	13.98%	17.96%	20.07%	21.03%
Profit (Net Income) Margin	-4.92%	-3.03%	3.36%	6.85%	-45.93%	-84.15%	15.59%	9.85%	10.20%	12.08%	13.01%
Tax Burden Percent	97.76%	124.92%	81.52%	96.83%	-11,142.81%	-2,547.81%	161.62%	83.07%	63.18%	62.20%	62.37%
Interest Burden Percent	147.48%	381.41%	47.12%	66.64%	7.28%	34.23%	66.91%	84.78%	89.87%	96.75%	99.15%
Effective Tax Rate	0.00%	0.00%	23.11%	20.14%	234.02%	28.20%	26.89%	20.80%	36.82%	37.80%	37.63%
Return on Invested Capital (ROIC)	-4.11%	0.37%	14.34%	19.36%	-9.62%	4.28%	4.01%	7.93%	9.13%	11.01%	12.82%
ROIC Less NNEP Spread (ROIC-NNEP)	-18.18%	-12.68%	-194.61%	-193.26%	-282.64%	-270.72%	10.00%	5.48%	6.43%	9.60%	11.39%
Return on Net Nonoperating Assets (RNNOA)	-8.16%	-7.31%	-6.92%	-3.44%	-61.28%	-69.58%	4.72%	3.07%	3.36%	3.27%	0.95%
Return on Equity (ROE)	-12.28%	-6.94%	7.42%	15.93%	-70.90%	-65.30%	8.73%	11.00%	12.49%	14.27%	13.77%
Cash Return on Invested Capital (CROIC)	19.02%	10.23%	-96.66%	120.88%	5.79%	102.14%	14.48%	-1.92%	-9.37%	-16.67%	-4.86%
Operating Return on Assets (OROA)	-3.14%	-0.56%	6.81%	6.69%	2.62%	3.41%	4.21%	8.12%	11.56%	13.68%	15.51%
Return on Assets (ROA)	-4.53%	-2.65%	2.62%	4.31%	-21.26%	-29.71%	4.55%	5.72%	6.57%	8.23%	9.59%
Return on Common Equity (ROCE)	-12.28%	-6.94%	7.42%	15.92%	-70.90%	-65.30%	8.73%	11.00%	12.49%	14.27%	13.76%
Return on Equity Simple (ROE_SIMPLE)	-12.95%	-7.11%	7.44%	14.61%	-106.56%	-99.91%	8.70%	10.45%	11.76%	13.77%	14.01%
Net Operating Profit after Tax (NOPAT)	-48	5.12	133	162	-132	123	182	360	361	347	320
NOPAT Margin	-2.39%	0.26%	6.73%	8.48%	-7.59%	6.93%	10.54%	11.07%	11.35%	12.48%	13.12%
Net Nonoperating Expense Percent (NNEP)	14.07%	13.06%	208.95%	212.63%	273.02%	275.00%	-5.99%	2.45%	2.70%	1.41%	1.43%
Return On Investment Capital (ROIC_SIMPLE)	-3.48%	0.35%	8.61%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	83.42%	84.02%	81.88%	81.67%	83.21%	80.08%	78.80%	80.32%	75.52%	74.08%	73.43%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	103.41%	99.63%	91.24%	90.14%	94.34%	90.35%	85.58%	86.02%	82.04%	79.93%	78.97%
Earnings before Interest and Taxes (EBIT)	-69	-13	173	203	98	172	248	455	572	558	513
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-36	25	210	239	134	203	277	539	666	624	560
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.47	0.92	1.38	2.62	2.81	1.56	0.96	1.63	2.26	2.76	2.93
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.56	0.39	0.63	1.23	1.21	1.32	1.71	1.54	1.96	2.42	2.72
Price to Earnings (P/E)	0.00	0.00	18.61	17.96	0.00	0.00	10.98	15.62	19.21	20.04	20.92
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	5.37%	5.57%	0.00%	0.00%	9.10%	6.40%	5.21%	4.99%	4.78%
Enterprise Value to Invested Capital (EV/IC)	1.35	0.95	1.24	4.53	2.07	2.64	1.12	1.41	1.81	2.20	2.61
Enterprise Value to Revenue (EV/Rev)	0.69	0.62	0.90	0.98	1.51	2.19	2.78	2.06	2.45	2.84	2.91
Enterprise Value to EBITDA (EV/EBITDA)	0.00	50.02	8.49	7.80	19.55	19.13	17.27	12.44	11.72	12.65	12.66
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	10.32	9.21	26.64	22.65	19.28	14.74	13.65	14.14	13.82
Enterprise Value to NOPAT (EV/NOPAT)	0.00	241.38	13.43	11.53	0.00	31.55	26.37	18.62	21.60	22.74	22.16
Enterprise Value to Operating Cash Flow (EV/OCF)	6.76	9.01	10.68	24.34	12.78	10.88	15.26	13.11	17.58	21.40	16.78
Enterprise Value to Free Cash Flow (EV/FCFF)	6.28	8.82	0.00	1.85	33.04	1.32	7.30	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.81	0.75	0.73	0.00	2.33	1.15	0.64	0.60	0.62	0.52	0.25
Long-Term Debt to Equity	0.78	0.73	0.71	0.00	2.33	1.15	0.64	0.60	0.61	0.52	0.25
Financial Leverage	0.45	0.58	0.04	0.02	0.22	0.26	0.47	0.56	0.52	0.34	0.08
Leverage Ratio	2.71	2.62	2.84	3.69	3.34	2.20	1.92	1.92	1.90	1.73	1.44
Compound Leverage Factor	4.00	10.01	1.34	2.46	0.24	0.75	1.28	1.63	1.71	1.68	1.42
Debt to Total Capital	44.67%	42.72%	42.21%	0.28%	69.97%	53.58%	39.00%	37.66%	38.19%	34.34%	20.07%
Short-Term Debt to Total Capital	1.49%	1.01%	0.97%	0.28%	0.00%	0.00%	0.01%	0.03%	0.49%	0.32%	0.37%
Long-Term Debt to Total Capital	43.19%	41.72%	41.25%	0.00%	69.97%	53.58%	39.00%	37.64%	37.70%	34.01%	19.70%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.02%	0.01%	0.00%	0.00%	0.00%	0.00%	0.01%	0.03%
Common Equity to Total Capital	55.33%	57.28%	57.79%	99.70%	30.02%	46.42%	61.00%	62.34%	61.81%	65.66%	79.90%
Debt to EBITDA	-17.38	25.61	3.10	0.01	13.03	8.51	7.12	3.44	2.56	2.04	1.02
Net Debt to EBITDA	-7.57	18.42	2.61	-2.02	3.84	7.61	6.63	3.16	2.34	1.85	0.80
Long-Term Debt to EBITDA	-16.80	25.01	3.03	0.00	13.03	8.51	7.12	3.43	2.53	2.02	1.00
Debt to NOPAT	-12.84	123.58	4.91	0.02	-13.25	14.03	10.87	5.14	4.72	3.67	1.78
Net Debt to NOPAT	-5.60	88.90	4.13	-2.99	-3.91	12.55	10.12	4.72	4.32	3.32	1.41
Long-Term Debt to NOPAT	-12.41	120.67	4.79	0.00	-13.25	14.03	10.87	5.14	4.66	3.64	1.75
Altman Z-Score	1.27	1.18	1.54	1.82	1.38	1.32	1.58	2.39	2.90	3.42	4.66
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.01%	0.03%	0.01%	0.00%	0.00%	0.00%	0.01%	0.03%	0.02%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.47	1.24	1.00	1.97	3.49	1.35	1.31	1.18	1.31	1.23	1.12
Quick Ratio	1.40	1.16	0.94	1.85	3.31	1.14	1.10	1.08	1.25	1.18	0.98
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	222	140	-895	1,012	79	2,945	656	-87	-370	-526	-121
Operating Cash Flow to CapEx	1,360.20%	422.27%	589.27%	1,106.20%	738.49%	1,856.41%	1,832.41%	1,955.56%	1,130.24%	1,361.88%	2,340.08%
Free Cash Flow to Firm to Interest Expense	5.46	3.34	-9.25	12.15	0.72	24.76	7.06	-1.17	-5.87	-22.74	-13.64
Operating Cash Flow to Interest Expense	5.07	3.26	1.73	0.92	1.85	3.01	3.38	6.86	7.03	15.95	47.54
Operating Cash Flow Less CapEx to Interest Expense	4.70	2.49	1.43	0.84	1.60	2.85	3.19	6.51	6.41	14.78	45.50
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.92	0.87	0.78	0.63	0.46	0.35	0.29	0.58	0.64	0.68	0.74
Accounts Receivable Turnover	7.56	7.01	6.59	7.03	5.13	3.78	3.41	6.51	6.77	6.98	7.65
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	35.06	26.79	27.50	26.12	23.30	21.82	16.11	28.71	34.10	37.15	38.73
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	48.26	52.07	55.39	51.92	71.17	96.49	107.05	56.05	53.89	52.32	47.71
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	48.26	52.07	55.39	51.92	71.17	96.49	107.05	56.05	53.89	52.32	47.71
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,034	1,305	1,440	412	1,262	1,472	4,294	4,768	4,320	3,589	2,716
Invested Capital Turnover	1.72	1.45	2.13	2.28	1.27	0.62	0.38	0.72	0.80	0.88	0.98
Increase / (Decrease) in Invested Capital	-271	-135	1,028	-850	-211	-2,821	-475	448	732	873	441
Enterprise Value (EV)	1,396	1,237	1,783	1,868	2,615	3,891	4,788	6,707	7,802	7,890	7,090
Market Capitalization	1,127	781	1,234	2,352	2,101	2,343	2,951	5,005	6,242	6,739	6,638
Book Value per Share	$8.91	$10.11	$10.73	$10.37	$8.73	$17.78	$34.53	$32.74	$29.48	$25.92	$22.55
Tangible Book Value per Share	($5.70)	($6.62)	($7.93)	($7.29)	($8.85)	($0.11)	($14.39)	($19.83)	($18.72)	($14.39)	($7.07)
Total Capital	1,383	1,482	1,543	899	2,490	3,229	5,062	4,919	4,466	3,713	2,834
Total Debt	618	633	651	2.49	1,743	1,730	1,975	1,853	1,706	1,275	569
Total Long-Term Debt	597	618	636	0.00	1,743	1,730	1,974	1,851	1,684	1,263	558
Net Debt	269	456	548	-485	514	1,548	1,837	1,702	1,560	1,151	451
Capital Expenditures (CapEx)	15	33	28	6.94	28	19	17	26	39	27	18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-122	-68	-87	-71	-124	7.31	90	27	93	50	7.28
Debt-free Net Working Capital (DFNWC)	226	109	16	416	1,105	190	157	97	160	111	61
Net Working Capital (NWC)	205	95	1.01	413	1,105	190	157	96	138	99	51
Net Nonoperating Expense (NNE)	51	66	66	31	665	1,621	-87	40	37	11	2.73
Net Nonoperating Obligations (NNO)	269	456	548	-485	514	-27	1,206	1,702	1,560	1,151	451
Total Depreciation and Amortization (D&A)	33	37	37	36	36	32	29	84	94	66	47
Debt-free, Cash-free Net Working Capital to Revenue	-6.08%	-3.43%	-4.42%	-3.74%	-7.13%	0.41%	5.23%	0.82%	2.93%	1.82%	0.30%
Debt-free Net Working Capital to Revenue	11.23%	5.49%	0.81%	21.75%	63.73%	10.66%	9.14%	2.99%	5.03%	3.99%	2.51%
Net Working Capital to Revenue	10.21%	4.74%	0.05%	21.62%	63.73%	10.66%	9.12%	2.94%	4.34%	3.56%	2.08%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.19)	$0.73	$0.79	$1.54	$0.00	($17.94)	$2.95	$3.47	$3.52	$3.61	$3.22
Adjusted Weighted Average Basic Shares Outstanding	83.33M	82.20M	83.47M	84.83M	0.00	83.50M	91.10M	92.43M	92.42M	93.08M	98.59M
Adjusted Diluted Earnings per Share	($1.19)	$0.73	$0.79	$1.53	$0.00	($17.94)	$2.93	$3.45	$3.49	$3.58	$3.18
Adjusted Weighted Average Diluted Shares Outstanding	83.33M	82.20M	84.12M	85.83M	0.00	83.50M	91.61M	92.96M	93.11M	93.96M	99.89M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$2.95	$3.47	$3.52	$3.61	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	85.83M	84.12M	83.03M	86.47M	0.00	84.28M	87.92M	93.80M	93.79M	93.80M	96.08M
Normalized Net Operating Profit after Tax (NOPAT)	122	110	154	186	120	167	182	360	361	347	320
Normalized NOPAT Margin	6.05%	5.54%	7.80%	9.71%	6.94%	9.39%	10.54%	11.07%	11.35%	12.48%	13.12%
Pre Tax Income Margin	-5.03%	-2.42%	4.13%	7.08%	0.41%	3.30%	9.65%	11.85%	16.14%	19.41%	20.85%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-1.69	-0.30	1.79	2.44	0.89	1.44	2.67	6.10	9.06	24.14	57.70
NOPAT to Interest Expense	-1.18	0.12	1.37	1.95	-1.19	1.04	1.95	4.83	5.72	15.01	35.98
EBIT Less CapEx to Interest Expense	-2.06	-1.07	1.49	2.35	0.64	1.28	2.49	5.75	8.44	22.97	55.67
NOPAT Less CapEx to Interest Expense	-1.55	-0.65	1.08	1.86	-1.44	0.87	1.77	4.48	5.10	13.84	33.95
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-1.72%	-1.52%	133.44%	3.60%	-1.07%	-9.70%	112.48%	21.91%	19.05%	70.02%	153.98%

This table displays calculated financial ratios and metrics derived from Pediatrix Medical Group's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-7.42%	1.19%	0.90%	0.74%	0.83%	-3.39%	3.41%	2.99%	1.82%	3.07%	-0.62%
EBITDA Growth	42.66%	145.41%	-18.93%	-357.33%	-32.97%	-324.17%	-12.43%	-2.41%	-18.71%	-40.54%	-17.19%
EBIT Growth	101.99%	135.24%	-16.00%	-425.22%	-47.10%	-409.37%	-15.01%	-3.30%	-23.18%	-47.01%	-19.40%
NOPAT Growth	189.15%	146.04%	-6.73%	-413.50%	-60.22%	-351.06%	-20.47%	-1.58%	-24.73%	-39.26%	-18.49%
Net Income Growth	413.93%	124.52%	-9.12%	-641.07%	-71.60%	-519.05%	-30.39%	4.22%	167.03%	-37.57%	-0.19%
EPS Growth	380.00%	124.67%	-11.54%	-641.18%	-70.59%	-528.57%	-29.73%	6.25%	168.00%	-36.36%	2.78%
Operating Cash Flow Growth	6.20%	92.07%	14.89%	20.10%	-24.09%	-29.83%	-4.07%	8.07%	-3.52%	123.09%	36.38%
Free Cash Flow Firm Growth	-400.98%	436.26%	1,753.56%	1,216.49%	659.68%	105.73%	104.87%	105.45%	102.78%	-210.66%	-36.71%
Invested Capital Growth	41.27%	-20.74%	-64.10%	-61.10%	-10.55%	-9.39%	-1.64%	-1.74%	0.70%	249.41%	286.52%
Revenue Q/Q Growth	-8.76%	-1.72%	1.36%	1.86%	-0.27%	-2.01%	1.21%	1.95%	-4.44%	4.88%	0.80%
EBITDA Q/Q Growth	-18.86%	15.05%	127.13%	-663.23%	125.83%	-305.37%	-13.88%	46.71%	-13.61%	-19.78%	-4.02%
EBIT Q/Q Growth	-18.30%	16.15%	121.45%	-1,092.47%	114.25%	-376.84%	-16.96%	61.44%	-16.64%	-23.95%	-5.52%
NOPAT Q/Q Growth	-34.05%	37.89%	123.60%	-1,447.10%	110.50%	-379.32%	-20.66%	70.92%	-33.72%	-11.51%	-1.82%
Net Income Q/Q Growth	-31.97%	56.78%	112.70%	-3,892.44%	103.25%	-681.02%	-24.37%	99.08%	-52.10%	-3.48%	13.24%
EPS Q/Q Growth	-35.14%	60.87%	112.50%	-3,780.00%	225.00%	-676.92%	-23.53%	100.00%	-51.43%	-5.41%	15.63%
Operating Cash Flow Q/Q Growth	-188.31%	44.83%	-14.13%	185.41%	-280.83%	-13.37%	-10.24%	188.24%	-202.26%	18.43%	1.12%
Free Cash Flow Firm Q/Q Growth	-204.99%	-68.55%	19.17%	664.94%	-84.17%	8.69%	-15.36%	341.41%	101.41%	7.73%	5.26%
Invested Capital Q/Q Growth	14.36%	94.63%	-10.10%	-29.40%	21.99%	-11.84%	-2.59%	62.34%	-35.00%	-4.30%	-2.69%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	8.22%	9.24%	7.89%	-29.49%	5.33%	-20.59%	9.82%	11.54%	8.02%	8.87%	11.60%
Operating Margin	7.00%	7.82%	6.62%	-31.28%	3.21%	-22.46%	7.95%	9.69%	6.12%	7.01%	9.67%
EBIT Margin	7.00%	7.82%	6.62%	-31.28%	3.21%	-22.46%	7.95%	9.69%	6.12%	7.01%	9.67%
Profit (Net Income) Margin	4.52%	6.07%	3.80%	-30.34%	0.82%	-25.04%	4.22%	5.65%	2.89%	5.77%	6.27%
Tax Burden Percent	73.82%	91.45%	77.04%	91.23%	51.57%	89.51%	69.38%	72.62%	68.59%	106.60%	79.08%
Interest Burden Percent	87.51%	84.82%	74.60%	106.34%	49.23%	124.54%	76.56%	80.31%	68.95%	77.21%	82.00%
Effective Tax Rate	26.18%	8.55%	22.96%	0.00%	48.43%	0.00%	30.62%	27.38%	31.41%	13.74%	25.87%
Return on Invested Capital (ROIC)	10.12%	12.31%	10.18%	-41.55%	3.73%	-22.85%	7.44%	9.16%	8.91%	12.88%	14.82%
ROIC Less NNEP Spread (ROIC-NNEP)	8.54%	10.81%	5.91%	-60.02%	-114.83%	-32.06%	6.31%	8.07%	-7.43%	8.40%	10.17%
Return on Net Nonoperating Assets (RNNOA)	1.94%	4.85%	1.08%	-16.80%	-0.46%	-18.49%	4.00%	5.77%	-0.33%	0.30%	1.13%
Return on Equity (ROE)	12.06%	17.17%	11.26%	-58.35%	3.28%	-41.34%	11.43%	14.93%	8.59%	13.18%	15.95%
Cash Return on Invested Capital (CROIC)	-37.85%	19.02%	79.05%	73.84%	10.60%	10.23%	9.36%	9.73%	12.44%	-96.66%	-101.87%
Operating Return on Assets (OROA)	6.65%	7.20%	6.03%	-29.12%	2.86%	-19.61%	6.87%	8.27%	5.20%	5.46%	7.60%
Return on Assets (ROA)	4.30%	5.59%	3.47%	-28.26%	0.73%	-21.87%	3.65%	4.82%	2.46%	4.49%	4.93%
Return on Common Equity (ROCE)	12.06%	17.17%	11.26%	-58.35%	3.28%	-41.34%	11.43%	14.93%	8.59%	13.18%	15.95%
Return on Equity Simple (ROE_SIMPLE)	-10.44%	0.00%	-34.65%	-35.65%	-8.24%	0.00%	9.66%	10.92%	11.18%	0.00%	9.80%
Net Operating Profit after Tax (NOPAT)	24	36	26	-110	8.20	-78	28	35	21	31	35
NOPAT Margin	5.17%	7.15%	5.10%	-21.89%	1.66%	-15.72%	5.52%	7.04%	4.20%	6.05%	7.17%
Net Nonoperating Expense Percent (NNEP)	1.58%	1.50%	4.26%	18.47%	118.56%	9.21%	1.13%	1.09%	16.34%	4.48%	4.65%
Return On Investment Capital (ROIC_SIMPLE)	1.69%	2.60%	-	-	-	-5.26%	-	-	-	2.01%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	86.32%	82.12%	82.76%	82.17%	86.72%	83.93%	84.05%	82.31%	85.80%	81.27%	81.80%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	93.00%	92.18%	93.38%	131.28%	96.79%	122.46%	92.05%	90.31%	93.88%	92.99%	90.33%
Earnings before Interest and Taxes (EBIT)	32	39	34	-158	16	-111	40	48	30	36	47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	38	46	40	-149	26	-102	50	58	39	46	57
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.58	1.47	1.36	0.90	0.98	0.92	1.10	1.26	1.36	1.38	1.62
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.63	0.56	0.50	0.32	0.42	0.39	0.53	0.60	0.63	0.63	0.71
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	11.38	11.55	12.10	18.61	16.54
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8.79%	8.66%	8.27%	5.37%	6.05%
Enterprise Value to Invested Capital (EV/IC)	1.38	1.35	1.49	0.88	0.98	0.95	1.07	1.16	1.35	1.24	1.35
Enterprise Value to Revenue (EV/Rev)	0.83	0.69	0.40	0.26	0.41	0.62	0.78	0.89	0.64	0.90	1.04
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	25.95	50.02	8.20	8.85	6.29	8.49	8.45
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	10.20	10.91	7.73	10.32	9.96
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	241.38	13.73	14.46	10.31	13.43	13.53
Enterprise Value to Operating Cash Flow (EV/OCF)	7.64	6.76	5.56	3.97	7.29	9.01	9.47	10.39	7.73	10.68	18.12
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	6.28	1.00	0.67	8.77	8.82	11.30	11.85	10.89	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.78	0.81	0.03	0.03	0.11	0.75	0.66	0.72	0.14	0.73	0.87
Long-Term Debt to Equity	0.75	0.78	0.00	0.00	0.09	0.73	0.64	0.71	0.13	0.71	0.85
Financial Leverage	0.23	0.45	0.18	0.28	0.00	0.58	0.63	0.71	0.04	0.04	0.11
Leverage Ratio	2.53	2.71	2.59	2.61	2.54	2.62	2.55	2.62	2.61	2.84	2.92
Compound Leverage Factor	2.21	2.30	1.93	2.77	1.25	3.27	1.95	2.10	1.80	2.19	2.40
Debt to Total Capital	43.70%	44.67%	2.56%	2.45%	10.12%	42.72%	39.67%	41.96%	12.41%	42.21%	46.49%
Short-Term Debt to Total Capital	1.58%	1.49%	2.56%	2.45%	1.72%	1.01%	0.93%	0.92%	1.44%	0.97%	0.93%
Long-Term Debt to Total Capital	42.12%	43.19%	0.00%	0.00%	8.40%	41.72%	38.74%	41.04%	10.98%	41.25%	45.56%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	56.30%	55.33%	97.44%	97.55%	89.88%	57.28%	60.33%	58.04%	87.59%	57.79%	53.51%
Debt to EBITDA	-25.24	-17.38	-0.10	-0.10	3.04	25.61	3.31	3.41	0.64	3.10	3.09
Net Debt to EBITDA	-16.21	-7.57	1.09	0.66	-0.60	18.42	2.66	2.89	0.13	2.61	2.68
Long-Term Debt to EBITDA	-24.33	-16.80	0.00	0.00	2.52	25.01	3.23	3.34	0.57	3.03	3.03
Debt to NOPAT	-16.67	-12.84	-0.13	-0.12	-20.17	123.58	5.54	5.58	1.05	4.91	4.95
Net Debt to NOPAT	-10.70	-5.60	1.31	0.77	3.99	88.90	4.45	4.72	0.21	4.13	4.29
Long-Term Debt to NOPAT	-16.07	-12.41	0.00	0.00	-16.74	120.67	5.41	5.45	0.93	4.79	4.85
Altman Z-Score	1.64	1.44	1.37	0.90	1.34	1.03	1.41	1.47	1.44	1.35	1.44
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.01%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.81	1.47	1.42	1.38	1.72	1.24	1.20	1.24	1.44	1.00	1.20
Quick Ratio	1.70	1.40	1.36	1.31	1.61	1.16	1.15	1.17	1.34	0.94	1.12
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-322	306	975	818	107	57	53	62	14	-997	-1,080
Operating Cash Flow to CapEx	-3,540.17%	0.00%	1,460.06%	1,536.21%	-2,349.46%	829.04%	873.26%	1,095.24%	-1,441.88%	1,003.62%	1,392.78%
Free Cash Flow to Firm to Interest Expense	-35.15	31.56	96.25	79.34	10.09	5.67	5.07	5.53	1.35	-100.15	-113.51
Operating Cash Flow to Interest Expense	-12.83	13.70	9.07	10.38	-11.81	6.87	7.71	7.93	-9.71	9.92	8.76
Operating Cash Flow Less CapEx to Interest Expense	-13.19	13.80	8.45	9.70	-12.32	6.04	6.82	7.21	-10.39	8.93	8.13
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.95	0.92	0.91	0.93	0.89	0.87	0.86	0.85	0.85	0.78	0.79
Accounts Receivable Turnover	7.51	7.56	7.11	7.35	7.11	7.01	7.04	6.90	6.64	6.59	7.03
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	35.11	35.06	34.29	33.04	27.14	26.79	27.41	27.43	27.25	27.50	27.14
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	48.60	48.26	51.31	49.67	51.36	52.07	51.86	52.87	54.95	55.39	51.89
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	48.60	48.26	51.31	49.67	51.36	52.07	51.86	52.87	54.95	55.39	51.89
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,183	1,034	531	591	837	1,305	1,480	1,519	936	1,440	1,505
Invested Capital Turnover	1.96	1.72	2.00	1.90	2.25	1.45	1.35	1.30	2.12	2.13	2.07
Increase / (Decrease) in Invested Capital	345	-271	-949	-928	-99	-135	-25	-27	6.53	1,028	1,115
Enterprise Value (EV)	1,637	1,396	794	520	824	1,237	1,579	1,767	1,264	1,783	2,039
Market Capitalization	1,244	1,127	995	635	843	781	1,067	1,190	1,238	1,234	1,393
Book Value per Share	$9.19	$8.91	$8.53	$8.40	$10.33	$10.11	$11.53	$11.25	$10.96	$10.73	$10.18
Tangible Book Value per Share	($5.40)	($5.70)	($6.05)	($6.45)	($6.71)	($6.62)	($6.90)	($7.24)	($7.71)	($7.93)	($8.21)
Total Capital	1,402	1,383	752	724	953	1,482	1,605	1,624	1,039	1,543	1,605
Total Debt	613	618	19	18	96	633	637	681	129	651	746
Total Long-Term Debt	590	597	0.00	0.00	80	618	622	666	114	636	731
Net Debt	393	269	-201	-115	-19	456	512	577	26	548	646
Capital Expenditures (CapEx)	3.32	-1.04	6.29	6.96	5.33	8.35	9.15	8.13	7.00	9.83	5.98
Debt-free, Cash-free Net Working Capital (DFCFNWC)	24	-122	-46	3.59	80	-68	-40	-12	36	-87	-13
Debt-free Net Working Capital (DFNWC)	243	226	174	137	196	109	85	92	139	16	87
Net Working Capital (NWC)	221	205	155	119	179	95	70	77	124	1.01	72
Net Nonoperating Expense (NNE)	2.96	5.45	6.62	43	4.16	46	6.55	6.94	6.40	1.43	4.40
Net Nonoperating Obligations (NNO)	393	269	-201	-115	-19	456	512	577	26	548	646
Total Depreciation and Amortization (D&A)	5.56	7.12	6.52	9.03	11	9.29	9.49	9.29	9.35	9.56	9.45
Debt-free, Cash-free Net Working Capital to Revenue	1.19%	-6.08%	-2.29%	0.18%	4.01%	-3.43%	-1.97%	-0.60%	1.84%	-4.42%	-0.67%
Debt-free Net Working Capital to Revenue	12.28%	11.23%	8.69%	6.83%	9.79%	5.49%	4.23%	4.63%	7.03%	0.81%	4.44%
Net Working Capital to Revenue	11.16%	10.21%	7.73%	5.95%	8.97%	4.74%	3.48%	3.88%	6.28%	0.05%	3.68%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.25	$0.37	$0.23	($1.84)	$0.05	($1.50)	$0.26	$0.34	$0.17	$0.35	$0.37
Adjusted Weighted Average Basic Shares Outstanding	84.44M	83.33M	83.89M	83.33M	82.86M	82.20M	82.54M	82.40M	81.89M	83.47M	82.13M
Adjusted Diluted Earnings per Share	$0.24	$0.37	$0.23	($1.84)	$0.05	($1.50)	$0.26	$0.34	$0.17	$0.35	$0.37
Adjusted Weighted Average Diluted Shares Outstanding	85.43M	83.33M	84.52M	83.33M	83.28M	82.20M	82.95M	82.66M	82.32M	84.12M	82.78M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	85.91M	85.83M	85.88M	85.87M	84.15M	84.12M	84.02M	83.94M	83.76M	83.03M	83.07M
Normalized Net Operating Profit after Tax (NOPAT)	29	58	40	27	13	-76	28	35	21	48	36
Normalized NOPAT Margin	6.23%	11.46%	7.90%	5.26%	2.54%	-15.41%	5.52%	7.04%	4.20%	9.34%	7.32%
Pre Tax Income Margin	6.13%	6.63%	4.94%	-33.26%	1.58%	-27.97%	6.09%	7.78%	4.22%	5.41%	7.93%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	3.51	4.05	3.34	-15.30	1.50	-11.06	3.88	4.32	2.89	3.62	4.98
NOPAT to Interest Expense	2.59	3.70	2.57	-10.71	0.77	-7.74	2.69	3.14	1.98	3.12	3.69
EBIT Less CapEx to Interest Expense	3.14	4.15	2.72	-15.98	1.00	-11.89	3.00	3.59	2.22	2.63	4.35
NOPAT Less CapEx to Interest Expense	2.23	3.81	1.95	-11.39	0.27	-8.57	1.81	2.41	1.31	2.14	3.06
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-2.90%	-1.72%	-0.42%	-0.41%	-1.46%	-1.52%	2.55%	23.07%	86.62%	133.44%	103.40%

Frequently Asked Questions About Pediatrix Medical Group's Financials

When does Pediatrix Medical Group's fiscal year end?

According to the most recent income statement we have on file, Pediatrix Medical Group's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Pediatrix Medical Group's net income changed over the last 10 years?

Pediatrix Medical Group's net income appears to be on an upward trend, with a most recent value of -$99.07 million in 2024, falling from $317.20 million in 2014. The previous period was -$60.41 million in 2023. See Pediatrix Medical Group's forecast for analyst expectations on what’s next for the company.

What is Pediatrix Medical Group's operating income?

Pediatrix Medical Group's total operating income in 2024 was -$68.71 million, based on the following breakdown:

Total Gross Profit: $2.01 billion
Total Operating Expenses: $2.08 billion

How has Pediatrix Medical Group revenue changed over the last 10 years?

Over the last 10 years, Pediatrix Medical Group's total revenue changed from $2.44 billion in 2014 to $2.01 billion in 2024, a change of -17.5%.

How much debt does Pediatrix Medical Group have?

Pediatrix Medical Group's total liabilities were at $1.39 billion at the end of 2024, a 1.2% increase from 2023, and a 3.4% increase since 2014.

How much cash does Pediatrix Medical Group have?

In the past 10 years, Pediatrix Medical Group's cash and equivalents has ranged from $9.82 million in 2022 to $1.12 billion in 2020, and is currently $229.94 million as of their latest financial filing in 2024.

How has Pediatrix Medical Group's book value per share changed over the last 10 years?

Over the last 10 years, Pediatrix Medical Group's book value per share changed from 22.55 in 2014 to 8.91 in 2024, a change of -60.5%.

Related Companies

This page (NYSE:MD) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pediatrix Medical Group (MD) Financials

Frequently Asked Questions About Pediatrix Medical Group's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pediatrix Medical Group (MD) Financials

Annual Income Statements for Pediatrix Medical Group

Quarterly Income Statements for Pediatrix Medical Group

Annual Cash Flow Statements for Pediatrix Medical Group

Quarterly Cash Flow Statements for Pediatrix Medical Group

Annual Balance Sheets for Pediatrix Medical Group

Quarterly Balance Sheets for Pediatrix Medical Group

Annual Metrics And Ratios for Pediatrix Medical Group

Quarterly Metrics And Ratios for Pediatrix Medical Group

Frequently Asked Questions About Pediatrix Medical Group's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools